tbuckley/cabot-search huggingface dataset:
Renal Transplantation
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Errata
Journal: Diabetes Care (2006)

S5, Table 2: The values for plasma glucose, FPG, and 2-h plasma glucose should appear as "Ն200 mg/dl (11.1 mmol/l)", "Ն126 mg/dl (7.0 mmol/l)", and "Ն200 mg/dl (11.1 mmol/l)," respectively.• S6, Table 3: The value for BMI should be "Ն25 kg/m 2 " in both places.• S12, line 11: The word "progression" should appear after "nephropathy".• S13: The head "Reduced calorie sweetners" should be "Reduced calorie sweeteners".• S24, lines 6 -7 under "Diagnosis of neuropathy": The phrase "dorsal surface of both great toes, just proximal to the nail bed, and ankle reflexes" should read "distal plantar aspect of both great toes, and ankle reflexes".• S27, Table 10: The A1C value for "Adolescents and young adults (13-19)" should be "Ͻ7.5%".
A molecular target of vascular calcification in chronic kidney disease
Authors: Mohamed G. Atta
Journal: Journal of Clinical Investigation (2022)

Vascular calcification (VC) causes cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD), particularly those with end-stage kidney disease (ESKD) on maintenance dialysis treatment. Although many mechanisms have been proposed, their detailed effects remain incompletely understood. In this issue of the JCI, Li et al. examined the molecular mechanism of the protective role of SIRT6 in VC in patients with CKD. Using in vitro and animal models of CKD, the authors demonstrated that SIRT6 prevents VC by suppressing the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs). Mechanistically, SIRT6 bound and deacetylated the runt-related transcription factor 2 (Runx2), a key transcription factor for osteogenic differentiation, promoting its nuclear export for proteasome degradation. These studies provide a pathway in the pathogenesis of VC and justify investigating SIRT6 as a potential target in CKD.
Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial
Authors: Mohammad Bosaeed, Ahmad Alharbi, Ebrahim Mahmoud, Sanaa Alrehily, Mohannad Bahlaq, Zied Gaifer, Hanan Alturkistani, Khaled Alhagan, Saad Alshahrani, Ali Tolbah, Abrar Musattat, Maha Alanazi, Raniah Jaha, Khizra Sultana, Hajar Alqahtani, Kholoud Al Aamer, Saud Jaser, Abdulrahman Alsaedy, Ayoub Ahmad, Mohammed Abalkhail, Sameera AlJohani, Majed Al Jeraisy, Sultan Almaziad, Nahlah Albaalharith, Khaled Alabdulkareem, Abdulmajeed Alshowair, Naif Khalaf Alharbi, Fahad Alrabiah, Majid Alshamrani, Omar Aldibasi, Ahmed Alaskar
Journal: Clinical Microbiology and Infection (2022)

To evaluate whether favipiravir reduces the time to viral clearance as documented by negative RT-PCR results for severe acute respiratory syndrome coronavirus 2 in mild cases of coronavirus disease 2019 (COVID-19) compared to placebo.
Diagnosis of Pulmonary Embolism on 99mTc-Labeled Macroaggregated Albumin Lung Imaging After Hepatic Arterial Injection for Planning of Radioembolization
Authors: Aubrey E. Frazzitta, Matthew D. Kay, Devdutta Warhadpande, Phillip H. Kuo
Journal: Clinical Nuclear Medicine (2022)

Abstract A 54-year-old man with hepatocellular carcinoma from alcohol-induced cirrhosis presented with hepatic encephalopathy and refractory ascites related to decompensated liver disease. MRI confirmed disease progression adjacent the site of prior radiofrequency ablation, performed 2 years prior, with associated right hepatic vein tumor thrombus. 99m Tc-labeled macroaggregated albumin lung shunt imaging performed before 90 Y radioembolization identified a left lower lobe wedge-shaped defect, confirmed as pulmonary embolism on CT pulmonary angiography and MRI.
Part 1: Abstracts from the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™
Authors: Idoroenyi Amanam, Nichole Young-Lin, Tuyen Kiet, Kevin Blansit, John Chan, Carlos Camps, Luis Paz-Ares, Manuel Codes, Rafael López, Pere Gascón, ; Juan, Jesús Cruz, Alfredo Carrato, Jesús García-Foncillas, Vicente Guillem, Eduardo Díaz-Rubio, Mark Chang, Nora Ruel, Sergio Villegas, Timothy Wilson, Nicholas Vogelzang, Bertram Yuh, Sumanta Pal
Journal: Journal of the National Comprehensive Cancer Network (2014)

Background: Given that various cancers have different survival outcomes and varying levels of unmet need, the end points of hazard ratio, response rate, and progression-free and overall survivals may not be sufficient to predict for FDA approval of novel drugs.The authors evaluated relative survival benefit (additional benefit/ historic control) as an end point to predict for oncology drug approval.Methods: Presentations and transcripts from Oncologic Drugs Advisory Committee (ODAC) sessions for drug license applications were reviewed.Relative survival benefit is defined as the percent improvement in survival associated with new therapy over standard therapy.The χ 2 test and logistical regression were used in SPSS.Results: Of 23 drug license applications reviewed from 2001 to 2012, 12 were approved by the FDA.These drug applications comprised 5 drugs for breast cancer, 3 for pancreatic cancer, 2 for renal cancer, 2 for prostate cancer, 2 for soft tissue sarcoma, 2 for lung cancer, 2 for ovarian cancer, 2 for bone metastasis, 2 for brain cancer, and 1 for skin cancer (Table 1).A total of 83% studies used only overall survival (OS) as a primary end point, whereas the remainder used progression-free survival (PFS).In all 24 studies, the median relative benefit was 10% (range, 3%-120%).Of the studies that used PFS (n=4) versus OS (n=20) as an end point, the average relative benefit was 90% (range, 40%-120%) and 10% (range, 0%-20%) (P=.02).Using the relative survival benefit of 10%, those with higher relative survival benefit had an approval rate of 61% versus 20% in those with lower AB2014-2.
A 5-year study of skin adnexal tumours in a large teaching hospital with implications for linked genetic diagnoses
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Cook et al. Br J Dermatol 2022; 186:167–173. Skin adnexal tumours (SATs) are a rare type of tumour (abnormal growth) found in children and adults. SATs of different types may develop from hair follicles, sebaceous glands or sweat glands. It is often difficult to diagnosis SATs. Certain types of these growths may also be linked to an underlying genetic (inherited) condition, some of which carry an increased risk of cancer in other parts of the body such as the bowel or kidney. Under a microscope, a skin biopsy (where a small section of tissue is removed for testing) can be examined and SATs diagnosed by skin pathology experts. We wanted to look at the types of SATs found, and to look for ways to identify patients with linked genetic diagnosis better. This study took place in a large hospital in the UK, where more than 100,000 skin samples were received by pathologists over 5 years. Of these samples, 1615 were SATs. We found that prior to biopsy, only 28% of doctors got the diagnosis right, showing the importance of expert skin pathologists in diagnosing SATs. Many of the types of SATs looked at in this study had potential links to a genetic diagnosis. Determining if this link was true often required more clinical information, which is not usually available to the pathologist. We propose that pathologists in their reports to clinicians flag up any potential linked genetic diagnosis. This will allow the clinician to appropriately assess the patient and decide if genetic testing may be needed. SATs can have healthcare implications for the affected patient and family if they are found to have a linked genetic diagnosis. Linked Article: Cook et al. Br J Dermatol 2022; 186:167–173.
Health, and How to Promote It.
Authors: None J. C. H.
Journal: JAMA (1884)

This is a small volume on private hygiene, the hygiene of the family, and is addressed more particularly to the non-professional reader. Avoiding scientific terms and tedious details, and dealing with his subject in an easy, pleasant style, the author has certainly presented his readers with a highly entertaining as well as instructive book, filled with valuable hints regarding the attainment and preservation of health, good morals, and happiness. Its pages are enlivened with witty remarks, pleasant anecdotes, and a kind of insinuating good humor calculated to improve the assimilating capacities of a confirmed dyspeptic, or even make an hypochondriac feel on better terms with himself. Altogether, it is one of the best books of the kind with which we are familiar.
Hypersensitivity Alveolitis
Authors: Vincent A. Marinkovich
Journal: JAMA (1975)

Hypersensitivity alveolitis developed in an 11-year-old girl during heavy exposure to mold spores contaminating the straw filters of an evaporation-type home air cooler. It is likely that the causative organism was<i>Micropolyspora faeni</i>, the mold responsible for farmer's lung. (<i>JAMA</i>231:944-947, 1975)
Non-invasive coronary bypass graft imaging after multivessel revascularisation Markus G. Engelmann, Andreas Knez, Alexander von Smekal, Bernd J. Wintersperger, Tanya Y. Huehns, Berthold H�fling, Maximilian F. Reiser, Gerhard Steinbeck. Medical Department I, University Hospital Gro�hadern, Munich, Germany, Institute for Diagnostic Radiology, University Hospital Gro�hadern, Munich, Germany
Journal: Journal of the American College of Cardiology (2001)
REFERENCES AND REVIEWS AND INTERNATIONAL COMMENTS
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An automated COVID-19 triage pipeline using artificial intelligence based on chest radiographs and clinical data
Authors: Chris K. Kim, Ji Whae Choi, Zhicheng Jiao, Dongcui Wang, Jing Wu, Thomas Y. Yi, Kasey C. Halsey, Feyisope Eweje, Thi My Linh Tran, Chang Liu, Robin Wang, John Sollee, Celina Hsieh, Ken Chang, Fang-Xue Yang, Ritambhara Singh, Jie-Lin Ou, Raymond Y. Huang, Cai Feng, Michael D. Feldman, Tao Liu, Ji Sheng Gong, Shaolei Lu, Carsten Eickhoff, Xue Feng, Ihab Kamel, Ronnie Sebro, Michael K. Atalay, Terrance Healey, Yong Fan, Wei-Hua Liao, Jianxin Wang, Harrison X. Bai
Journal: npj Digital Medicine (2022)

While COVID-19 diagnosis and prognosis artificial intelligence models exist, very few can be implemented for practical use given their high risk of bias. We aimed to develop a diagnosis model that addresses notable shortcomings of prior studies, integrating it into a fully automated triage pipeline that examines chest radiographs for the presence, severity, and progression of COVID-19 pneumonia. Scans were collected using the DICOM Image Analysis and Archive, a system that communicates with a hospital's image repository. The authors collected over 6,500 non-public chest X-rays comprising diverse COVID-19 severities, along with radiology reports and RT-PCR data. The authors provisioned one internally held-out and two external test sets to assess model generalizability and compare performance to traditional radiologist interpretation. The pipeline was evaluated on a prospective cohort of 80 radiographs, reporting a 95% diagnostic accuracy. The study mitigates bias in AI model development and demonstrates the value of an end-to-end COVID-19 triage platform.
JHEP at a glance (November 2020)
Authors: Ravi Rai, Yunshan Liu, Smita Iyer, Mark Czaja, Frank Anania, Reben Raeman, Hannes Hagström, Mats Talbäck, Anna Andreasson, Göran Walldius, Niklas Hammar, Peter Jepsen, Frederik Kraglund, Joe West, Gerda Villadsen, Henrik Sørensen, Hendrik Vilstrup, Massimo Iavarone, Roberta Ambrosio, Alessandro Soria, Pietro Invernizzi, Paolo Bonfanti, Pietro Lampertico, Jonel Trebicka, Wenyi Gu, Luis Ibáñez- Samaniego, Juan Carlos, Christian Jansen, Rafael Bañares, Archita Desai, Shannon Knapp, Eric Orman, Pere Ginès, Naga Chalasani, Kavish Patidar, Min Zhang, Hui Yang, Xuetao Pei, Bing Liu, Xinlong Yan
Journal: Journal of Hepatology (2020)
Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma.
Authors: Yonggui Hong, Tao Wu, Ping Lu, Zhiwei Chang, Wei Liang, Guifang Zhang, Junsheng Wang
Journal: Journal of Clinical Oncology (2022)

320 Background: Anti-PD-1 mAb treatment has been shown to be effective in the treatment of esophageal cancer. Anlotinib has been approved in China as a second-line treatment for advanced esophageal cancer because of its good tolerance and efficacy. In the treatment of esophageal cancer, antiangiogenic target therapy combined with immunotherapy has been preliminarily recognized internationally. The purpose of this study is to investigate the efficacy and safety of anlotinib in combination with PD-1 inhibitors in second-line or later therapy during the treatment of esophageal cancer in the real world setting.(A LOT-EC3, NCT04966611). Methods: This is a prospective, multicenter real-world study. The esophageal cancer patients who received anlotinib in combination with PD-1 inhibitors in second-line or later therapy were enrolled. The primary endpoint was PFS (progression-free survival), and secondary endpoints were ORR (objective response rate), DCR (disease control rate) and OS (overall survival). The response to treatment was evaluated according to RECIST version 1.1. In addition, adverse events were evaluated by CTCAE v5.0. Results: From Jul 2020 to Sep 2021, 40 patients with a median age of 65.5 (range: 48̃81) were enrolled, in which the metastasis of more than 1 organ occurred in 62.5% of the 40 patients; the metastasis of more than 2 organs occurred in 37.5% (15 patients). 26 (65.0%) and 14 (35.0%) patients received anlotinib combined with PD-1 inhibitors as second line and third &amp; above line therapy, respectively. Among all patients, 1 patient achieved complete response (CR), 11 patients partial response (PR), 23 patients stable disease (SD), illustrating an ORR of 30.0% and a DCR of 87.5%. In the second line therapy, ORR was 30.8 %, DCR was 92.3%. In the third &amp; above line, ORR with 28.6%, DCR with 78.6% was observed. Median PFS was not reached. For all the 40 patients, 27 of which were treated with Camrelizumab, 10 were treated with Sintilimab, other 3 patients were treated with other kinds of PD-1 inhibitors. There was no significant difference in DCR between different PD-1 inhibitors. Treatment related adverse events (trAEs) occurred in 22 (55%) patients. 4 patients had grade 3 or more trAEs. No patient died due to trAE. Conclusions: Anlotinib combined with PD-1 inhibitors is found to be a reasonable option in second-line or later therapy for the treatment of advanced esophageal cancer. To our best knowledge, this is the first summarized real-world study on anlotinib combined with PD-1 inhibitors in advanced esophageal cancer. The treatment effects are similar to the outcomes in comparable clinical trials, which support the further recommendation of anlotinib combined with PD-1 inhibitors in the treatment of esophageal cancer. Clinical trial information: NCT04966611.
Troponin I predicts adverse outcome after percutaneous coronary intervention in patients with chronic renal failure Luis Gruberg, Shmuel Fuchs, Roxana Mehran, Lowell F. Satler, Augusto D. Pichard, Kenneth M. Kent, Rakefet Einav-Gruberg, Natalie Gevorkian, Hongsheng Wu, Ron Waksman. Washington Hospital Center, Washington, DC
Journal: Journal of the American College of Cardiology (2001)
Medical News
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comment on Lee et al. Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study. Diabetes Care 2021;44:2419–2426
Authors: Sylvie Feldman-Billard, Michel Paques
Journal: Diabetes Care (2022)
Single‐dose versus low‐dose rituximab in corticosteroid‐resistant or relapsed <scp>ITP</scp>: A multicenter, randomized, controlled study
Authors: Xiaofei Ni, Daqi Li, Chenglu Yuan, Yafei Yu, Haoyi Wang, Lingjun Wang, Tianshu Yu, Ping Qin, Jun Peng, Ming Hou, Yan Shi, Yu Hou
Journal: American Journal of Hematology (2022)

Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder, in which rituximab (RTX) induces the best long-term effect among recommended second-line treatments. Nevertheless, the optimal regimen of RTX remains unclear. We herein conducted a prospective, multicenter, open-label, randomized controlled trial to compare the efficacy and safety of RTX at two different dosage regimens in patients with corticosteroid-resistant or relapsed ITP. Recruited patients were randomly assigned (1:1) to receive either RTX at a repeated low dose (100 mg weekly for 4 weeks, LD-RTX) or at a single dose (375 mg/m2 , S-RTX). Overall response was achieved in 64.3% of patients who received LD-RTX versus 67.4% of those receiving S-RTX (p = .759). The complete response (CR) rate was 23.8% after LD-RTX and 28.3% after S-RTX (p = .635). In health-related quality of life, S-RTX improved patients' psychological status, quality of life, social activities, and work compared with LD-RTX. Furthermore, S-RTX significantly reduced physician visits without compromising efficacy. Our findings demonstrate that a S-RTX is comparable to LD-RTX in effectiveness and safety for treatment of corticosteroid-resistant or relapsed ITP. The single-dosage regimen optimizes the use of medical resources, improves the cost-effectiveness of RTX, and represents a promising and more convenient replacement for LD-RTX in ITP. This study has been completed and is registered with ClinicalTrials.gov, number NCT03258866.
Do patients benefit from participating in the German skin cancer screening programme?
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Datzmann et al. Br J Dermatol 2022; 186:69–77. The German skin cancer screening programme began in 2008 with the aim of reducing deaths from skin cancer by detecting skin cancers early, when they are more easily treated. More than 10 years after its launch, the benefits and risks of the programme are still unclear. In this study, we compared deaths in patients with newly diagnosed melanoma who participated in the German skin cancer screening programme between the years of 2010 and 2016 with deaths in patients who did not. Melanoma is a serious form of skin cancer that occurs mostly in older people. In Europe, about 20 new cases of melanoma per 100,000 people are diagnosed per year, with numbers rising over recent years. We used health insurance data from over 1,400,000 people. We identified people with newly diagnosed melanoma and calculated the survival times for those who did and did not participate in the screening programme. Patients who had participated in screening had lower death rates than patients who had not undergone screening. To make the comparison as fair as possible, we took account of differences in age, sex, education, other health conditions, voluntary vaccinations and health check-ups in our analysis, as well as starting treatment within 30 days of their initial melanoma diagnosis. After controlling for these aspects, screening participants still showed a survival advantage. People in the screening programme were initially diagnosed with less severe melanoma and therefore had fewer radical treatments than the other patients. However, we cannot exclude the possibility of bias in the results, for example, because healthier people may have participated in the screening programme as they may be more active and health conscious. Further data on the effectiveness of the programme are needed, however, if our results are confirmed, this would suggest that the German skin cancer screening programme should be continued. Linked Article: Datzmann et al. Br J Dermatol 2022; 186:69–77.